Controlled document PF-014A
PLEXUS LUMBALIS Phase 2 Master Formula
Record identification
- Document ID
- PF-014A
- Document type
- Template
- Status
- Documented
- Source
- Standardisation & Production of SIRIAM Products
Overview
PF-014A
PRODUCT FORMULA CARD
SIRIAM PLEXUS LUMBALIS DUO – PHASE 2 (NERVE INTEGRATION)
DOCUMENT CONTROL
Field
Product ID
Formula ID
Document
Product
Anatomical Region
Therapeutic Phase
Product Type
Standard Batch
Version
Status
Internal QR
| Value |
|---|
| SIR-PL-002 |
| MF-014 |
| PF-014A |
| PLEXUS LUMBALIS DUO – Phase 2 |
| L2–L4 |
| Nerve Integration |
| Topical Magistral Cream |
| 100 g |
| 2.0 |
| 🔒 LOCKED |
| ☐ |
1. PRODUCT PURPOSE
Field
Clinical Objective
Anatomical Region
Primary Biological Target
Therapeutic Phase
Product Type
| Description |
|---|
| Neurodermal stabilisation of the lumbar plexus |
| L2–L4 |
| Fascial integration, neuromuscular recovery and autonomic harmonisation |
| Phase 2 – Integration |
| Topical Magistral Cream |
2. MASTER FORMULA
The formulation reflects the uploaded Phase 2 magistral fiche with the agreed SQMS nomenclature.
| Code |
|---|
| Official Ingredient |
| Supplier |
| Master Qty |
| Unit |
| Phase |
| PC-001 |
| Lanette Cream FNA |
| Fagron |
| 67.00 |
| g |
| B |
| PC-002 |
| Aqua Purificata |
| Fagron |
| 16.00 |
| g |
| W |
| SC-001 |
| Magnesium Chloride |
| Fagron |
| 2.00 |
| g |
| W |
| SC-002 |
| MSM |
| — |
| 2.00 |
| g |
| W |
| AC-003 |
| Palmitoylethanolamide (PEA) |
| Vitals |
| 1.50 |
| g |
| D |
| BE-001 |
| Boswellia serrata |
| WeightWorld |
| 0.33 |
| g |
| D |
| BE-013 |
| Solidago virgaurea |
| A.Vogel |
| 0.20 |
| mL |
| C |
| BE-009 |
| Ruta graveolens |
| — |
| 0.20 |
| mL |
| C |
| BE-004 |
| Bacopa monnieri |
| Mattisson |
| 0.70 |
| mL |
| C |
| BE-005 |
| Nymphaea caerulea (Blue Lotus) |
| — |
| 1 drop / 300 g |
| drop |
| C |
| BE-002 |
| Copaiba Oil |
| Aroma-Zone |
| 0.60 |
| mL |
| C |
| AC-002 |
| Betaine (TMG) |
| — |
| 0.50 |
| g |
| W |
| AC-005 |
| Taurine |
| — |
| 0.30 |
| g |
| W |
| SC-003 |
| D-Panthenol |
| Natural Heroes |
| 1.20 |
| g |
| W |
| SC-004 |
| Vitamin E Full Spectrum |
| Natural Heroes |
| 0.70 |
| g |
| L |
| SC-005 |
| Silicea Gel (+1 drop Silicea D8) |
| — |
| 2.00 |
| g |
| C |
| PR-001 |
| Cosgard 221 |
| Aromantic |
| 0.70 |
| g |
| C |
3. MANUFACTURING WORKFLOW
Standard SQMS Lanette Manufacturing Workflow (SOP-001), including pre-dispersion of PEA and Boswellia and addition of Bacopa/Blue Lotus below 35°C.
4. QUALITY CONTROL
Standard SQMS Quality Control checklist.
5. BATCH RELEASE
Standard SQMS Batch Release form.
6. CLINICAL APPLICATION
Field
Anatomical Region
Primary Zone
Secondary Zone
Additional Zone
Posterior Zone
Additional Posterior Zone
Frequency
Weeks 1–2
Week 3
Week 4
Week 5
Relapse
Treatment protocol follows the magistral fiche.
| Value |
|---|
| L2–L4 |
| Inguinal region |
| ASIS projection |
| Femoral triangle |
| Paravertebral L2–L4 |
| Quadratus lumborum & posterior iliac crest |
| 1–2× daily |
| PLEXUS LUMBALIS-1 |
| Morning PLEXUS LUMBALIS-2 / Evening PLEXUS LUMBALIS-1 |
| PLEXUS LUMBALIS-2 |
| PLEXUS LUMBALIS-2 (evening) |
| 3 days PLEXUS LUMBALIS-1 |
Related documents
Platform modules